Biocon Biologics expands its partnership with Civica, Inc. to launch a private-label Insulin Glargine, broadening access to diabetes treatment in the U.S. This collaboration aims to provide more affordable insulin options for the 38.4 million Americans living with diabetes. Biocon will manufacture and supply the insulin, while Civica will commercialize it, increasing the availability of high-quality insulins. This expands on a prior agreement relating to Insulin Aspart.
Expanding Diabetes Treatment Access
Biocon Biologics Ltd. (BBL) is extending its collaboration with Civica, Inc. to include a new Insulin Glargine medicine. This initiative seeks to benefit patients in the United States by increasing the supply of high-quality, affordable insulins.
Partnership Details
The agreement establishes an exclusive distributorship where Biocon Biologics will manufacture and supply Insulin Glargine to Civica. Civica will then commercialize it under Biocon Biologics’ existing marketing approval, essentially creating a private label agreement. The distribution will occur in the U.S. under a separate Civica label, including the CalRx brand in California.
Strategic Impact
Shreehas Tambe, CEO of Biocon Biologics, stated the company’s commitment to expanding access to affordable, high-quality insulins in the U.S. and globally. He emphasized that extending the collaboration with Civica builds on their approach to enhancing patient access. He mentioned it allows them to reach underserved populations through new channels.
Prior Agreement
This new agreement builds upon a previous relationship where Biocon Biologics agreed to supply Civica with Insulin Aspart drug substance for manufacturing in the United States.
Diabetes Statistics
There are approximately 38.4 million people with diabetes in the United States. This represents about 11.6% of the total population, with nearly a quarter of these cases remaining undiagnosed. An additional 97.6 million Americans have been identified as prediabetic.
Source: BSE
